United States: Issue Of Whether Government Must Allege Specific False Claims In FCA Case Predicated On Alleged Kickbacks Is Teed Up In Southern District Of New York

Last Updated: January 13 2014
Article by Todd R. Geremia

A motion to dismiss in United States et al. v. Novartis Pharmaceuticals Corp. ("Novartis"), 11 Civ. 0071 (PGG), fully briefed as of December 23, 2013, could have significant consequences for the application of Federal Rule of Civil Procedure 9(b) to cases brought under the False Claims Act ("FCA") in the Southern District of New York. The case, a qui tam in which the United States intervened, alleges that for 10 years, Novartis engaged in a nationwide scheme of fraudulent speaker programs to induce doctors to prescribe Novartis pharmaceuticals in violation of the Anti-Kickback Statute ("AKS"). After the Government filed an amended complaint on August 26, 2013, Novartis moved to dismiss based primarily on Rule 9(b), which requires that fraud be pled with particularity. A key issue raised by the motion to dismiss is whether, in an action brought under the FCA based on AKS violations, the Government is required at the pleading stage to identify particular false claims that were submitted for payment by federal health care programs as a result of the alleged kickback scheme. That issue, which has not yet been decided by the Second Circuit, is one of the most frequently contested in FCA jurisprudence today.


The original qui tam complaint in the Novartis case was filed under seal by Oswald Bilotta, a former sales representative at Novartis, on January 5, 2011. On April 26, 2013, the Government intervened in part and filed a complaint alleging that from 2002 through 2011, Novartis "systematically paid doctors to speak about certain of its drugs, including its cardiovascular drugs Lotrel and Valturna and its diabetes drug Starlix, at events that were often little or nothing more than social occasions for the doctors," including dinners.1 The Government alleged that "[t]he payments to the doctors, and the dinners, were kickbacks to the speakers and the attendees to induce them to write prescriptions for Novartis drugs."2

After Novartis notified the court of its intention to move to dismiss the complaint, the court held a pre-motion conference on July 18, 2013. At the conference, the court indicated that it had "concerns" about whether the Government's complaint satisfied Rule 9(b).3 The court stated that "while the complaint contains substantial details about the alleged kickback scheme, [the court was] concerned that it may not satisfy Rule 9(b) because it lacks sufficient detail about the claims submission process and does not provide examples of specific fraudulent claims that were submitted."4 Citing United States ex rel. Polansky v. Pfizer, Inc., 2009 WL 1456583, at *5 (E.D.N.Y. May 27, 2009), the court noted that "[u]nder the FCA liability attaches 'not to the underlying fraudulent activity or to the government's wrongful payment, but to the claim for payment.'"5 The court further noted that "[a]ccordingly, many courts have held that FCA pleadings are 'inadequate unless they are linked to allegations, stated with particularity, of actual false claims submitted to the government that constitute the essential element of an FCA qui tam action.'"6 The court stated that:

As the Eleventh Circuit stated in the much-[cited] case of United States ex rel. Clausen v. Laboratory Corporation of America, Inc., "the submission of a claim [is] the sine qua non of a false claims act violation." As such, Rule 9(b)'s directive that "the circumstances constituting fraud or mistake shall be stated with particularity" does not permit a False Claims Act plaintiff merely to describe a private scheme in detail but then to allege simply and without any stated reason for his plea that claims requesting illegal payments must have been submitted, were likely submitted, or should have been submitted to the government. "If Rule 9(b) is to be adhered to, some indicia of reliability must be given in the complaint to support the allegation of an actual false claim for payment being made to the government." 290 F.3d 1301, 1311 (11th Cir. 2002).7

The court gave the Government the option of amending its complaint within 30 days following the conference.8

The Motion to Dismiss

On August 26, 2013, the Government filed an amended complaint.9 Novartis moved to dismiss it on October 24, 2013.10 Novartis argued, among other things, that "[a]lthough the Amended Complaint now identifies (by their initials) fifteen doctors and attaches spreadsheets of each doctor's total prescriptions of the NPC drugs at issue during the challenged time period, it makes no attempt to tie those prescriptions (and the resulting allegedly false claims) to an allegedly sham speaker event—something it clearly must do in order to meet the requirements of Rule 9(b)."11 Citing United States ex rel. Karvelas v. Melrose-Wakefield Hosp., 360 F.3d 220 (1st Cir. 2004), Novartis argued that "Rule 9(b) requires an FCA complaint to allege 'with particularity' 'the actual false claims submitted to the government' in addition to the '[u]nderlying schemes and other wrongful activities that result[ed] in the submission of fraudulent claims.'"12

In its opposition to the motion, the Government took a diametrically opposed position on whether Rule 9(b) requires a plaintiff to particularize false claims in a case brought under the FCA for AKS violations. The Government argued that:

To plead FCA claims based on an AKS violation, the Government "need not identify particular claims resulting from the kickback scheme." Parikh, 2013 WL 5304057, at *7. Rather, Rule 9(b) requires only that the Government "plead with particularity that [Novartis] made kickbacks with the intent of inducing [prescriptions], and ... plead "particular details of a scheme ... paired with reliable indicia that lead to a strong inference that claims were actually submitted." Id. (quoting Grubbs, 565 F.3d at 190); see United States ex rel. Simpson v. Bayer Corp., No. 05-3895, 2013 WL 4710587, at *13-14 (D.N.J. Aug. 30, 2013).13

Moreover, the Government argued that it had "gone further," claiming that "[t]he Complaint ... identifies thousands of tainted prescriptions that were submitted for reimbursement and resulted in false claims."14

The Government disagreed with Novartis's position that "the Complaint must connect a particular sham event with a particular fraudulently induced prescription to satisfy Rule 9(b)."15 The Government maintained that once it "shows that a doctor received remuneration in violation of the AKS during a particular period, all claims for reimbursement from federal health care programs associated with that doctor during that period are false because payment by the Government is contingent upon the doctor's continued compliance with the AKS."16 Furthermore, the Government argued that "[e]ven if the Government were required to establish a causal link between particular sham events and particular prescriptions—which it is not—the Government would not have to plead such a link."17 According to the Government, "courts have concluded that '[a plaintiff] need not allege a relationship between the alleged AKS violations and the claims ... submitted to the Government.'"18

In its reply, Novartis contends that the Government's "proposed pleading standard is based on case[]law from other jurisdictions; those cases are flatly inconsistent with Second Circuit precedent; and they all involve a private relator plaintiff, not the government, which is empowered to conduct pre-suit investigations."19 Novartis argues that the Government's reliance on United States ex rel. Grubbs v. Kanneganti, 565 F.3d 180 (5th Cir. 2009), was misplaced because "[n]ot only did Grubbs involve a relator plaintiff (and not the government), but it has been expressly rejected by courts in the Second Circuit."20 Novartis asserts that decisions by the Eastern District of New York, United States ex rel. Moore v. Gaxosmithkline, LLC, No. 06-cv-6047, slip op. at 7-8 (E.D.N.Y. Oct. 16, 2013), United States ex rel. Mooney v. Americare, Inc., No. 06-cv-1806, 2013 WL 1346022 (E.D.N.Y. Apr. 3, 2013), and United States ex rel. Piacentile v. Novartis AG, No. 04-cv-4265, slip op. (E.D.N.Y. Feb. 7, 2011), support its argument that Rule 9(b) requires particularized allegations of false claims.21


As the parties' briefing in the Novartis action reflects, courts have differed on whether or not, in a case brought under the FCA based on alleged kickback violations, a plaintiff is required to identify specific false claims resulting from the alleged kickback scheme that were presented for payment by federal health care programs. In Grubbs, relied on by the Government in its opposition to Novartis's motion to dismiss, the Fifth Circuit held that a relator is not required to identify specific false claims at the pleading stage in order to survive a Rule 9(b) challenge. The court stated that:

[T]o plead with particularity the circumstances constituting fraud for a False Claims Act ... claim, a relator's complaint, if it cannot allege the details of an actually submitted false claim, may nevertheless survive by alleging particular details of a scheme to submit false claims paired with reliable indicia that lead to a strong inference that claims were actually submitted.22

By contrast, in United States ex rel. Bledsoe v. Cmty. Health Sys., Inc., 501 F.3d 493, 504 (6th Cir. 2007), cited by Novartis, the Sixth Circuit held that "pleading an actual false claim with particularity is an indispensable element of a complaint that alleges a FCA violation in compliance with Rule 9(b)." The First, Fourth, Seventh, Eighth, Ninth, and Tenth Circuits have also issued decisions on the issue.23

The Second Circuit has not yet ruled on the issue. Moreover, neither Novartis nor the Government has argued in the motion to dismiss briefing that the issue of whether the Government is required to plead specific false claims that resulted from the alleged kickback scheme has previously been decided by any judge in the Southern District of New York.


1.  Complaint in Intervention of the United States of America at ¶1.

2.  Id.

3.  Transcript of Pre-Motion Conference at 3.

4.  Id. at 18.

5.  Id. at 8.

6.  Id.

7.  Id. at 9.

8.  Id. at 18.

9.  Amended Complaint in Intervention of the United States of America.

10. Novartis Pharmaceuticals Corporation's Memorandum of Law in Support of its Motion to Dismiss the Amended Complaint in Intervention of the United States of America.

11. Id. at 3.

12. Id. at 7.

13. The United States of America's Memorandum of Law in Opposition to Defendant's Motion to Dismiss at 10.

14. Id.

15. Id. at 10-11.

16. Id. at 11.

17. Id.

18. Id. (citing Simpson, 2013 WL 4710587, at *14 (quoting Wilkins, 659 F.3d at 313)) (internal quotations omitted).

19. Novartis Pharmaceuticals Corporation's Reply Memorandum of Law in Support of its Motion to Dismiss the Amended Complaint in Intervention of the United States of America at 2.

20. Id. at 3 (citing United States v. Wells Fargo Bank, N.A., No. 12-cv-7527, 2013 WL 5312564, at *18 n. 17 (S.D.N.Y. Sept. 24, 2013).

21. Id. at 7, n. 6.

22. 565 F.3d at 190.

23. See United States ex rel. Duxbury v. Ortho Biotech Prods., L.P. 579 F.3d 13, 29 (1st Cir. 2009) (in qui tam alleging defendant induced third parties to file false claims with the government, "relator could satisfy Rule 9(b) by providing factual or statistical evidence to strengthen the inference of fraud beyond [mere] possibility without necessarily providing details as to each false claim") (internal quotations omitted), cert. denied, 130 S.Ct. 3454 (2010); United States ex rel. Lusby v. Rolls-Royce Corp., 570 F.3d 849, 854-55 (7th Cir. 2009) (relator not required by Rule 9(b) to allege "specific request for payment"); United States ex rel. Joshi v. St. Luke's Hospital, Inc., 441 F.3d 552, 556-57 (8th Cir.) (affirming dismissal under Rule 9(b) where relator "did not allege any details concerning false claims actually submitted for payment"), cert. denied, 549 U.S. 881 (2006); United States ex rel. Cafasso v. General Dynamics C4 Sys., Inc., 637 F.3d 1047, 1055-56 (9th Cir. 2011) ("[a]n actual false claim is the sine qua non of an FCA violation"; complaint failed to satisfy Rule 9(b) where it did not plead false claim or "warrant an inference that false claims were part of the scheme alleged"); Ebeid ex rel. United States v. Lungwitz, 616 F.3d 993, 998-999 (9th Cir.) (relator not required by Rule 9(b) to identify "representative examples of false claims," if complaint provides "reasonable indicia that false claims were actually submitted"), cert. denied, 131 S.Ct. 801 (2010); United States ex rel. Envirocare of Utah, Inc., 614 F.3d 1163, 1172 (10th Cir. 2010) ("claims under the FCA need only show the specifics of a fraudulent scheme and provide an adequate basis for a reasonable inference that false claims were submitted as part of that scheme"); United States ex rel. Sikkenga v. Regence BlueCross BlueShield, 472 F.3d 702, 727 (10th Cir. 2006) (Rule 9(b) not satisfied where complaint lacks "allegations, stated with particularity, of the actual false claims submitted to the government") (internal quotations omitted); Hopper v. Solvay Pharmaceuticals, Inc., 588 F.3d 1318, 1326 (11th Cir. 2009) (affirming dismissal of complaint that "d[id] not allege the existence of a single actual false claim"), cert. denied, 130 S.Ct. 3465 (2010); United States ex rel. Clausen v. Lab. Corp. of America, Inc., 290 F.3d 1301, 1311-12 (11th Cir. 2002) (Rule 9(b) requires dismissal of FCA complaint unless it identifies actual false claims for payment), cert. denied, 537 U.S. 1105 (2003).

Recently, in a non-intervened qui tam case, United States ex rel. Nathan v. Takeda Pharmaceuticals North America, Inc., 707 F.3d 451 (4th Cir. 2013), petition for cert. filed on May 10, 2013, the Supreme Court requested the views of the Solicitor General on a petition for certiorari where the relator's question presented is "[w]hether Rule 9(b) requires that a complaint under the False Claims Act 'allege with particularity that specific false claims actually were presented to the government for payment.'" In response to a prior request for views, in Duxbury, the Solicitor General advised the Supreme Court that the courts of appeals were divided on the issue.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions